InterMune reports positive interim Phase II data for hepatitis C protease inhibitor
This article was originally published in Scrip
Executive Summary
InterMune's hepatitis C protease inhibitor danoprevir has achieved better rates of rapid virologic response (RVR) and complete early virologic response (cEVR) than the current standard of care in a Phase IIb study.